Treatment for COVID-19-a cohort study from Northern Italy.
Adrenal Cortex Hormones
/ administration & dosage
Aged
Antibodies, Monoclonal, Humanized
/ administration & dosage
Antiviral Agents
/ administration & dosage
Azithromycin
/ administration & dosage
COVID-19
/ epidemiology
Female
Heparin
/ administration & dosage
Hospital Mortality
Hospitalization
Humans
Italy
/ epidemiology
Male
Middle Aged
Patient Admission
Probability
Proportional Hazards Models
Retrospective Studies
SARS-CoV-2
Treatment Outcome
COVID-19 Drug Treatment
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
25 10 2021
25 10 2021
Historique:
received:
05
02
2021
accepted:
31
08
2021
entrez:
26
10
2021
pubmed:
27
10
2021
medline:
16
11
2021
Statut:
epublish
Résumé
Multicentre, retrospective cohort study with multivariable Cox proportional-hazards modelling and survival-time inverse-probability-weighting, evaluating the impact of different treatments on survival of proven COVID-19 patients admitted to two Hospitals in the province of Piacenza, Italy. Use of tocilizumab and of high doses of low molecular weight heparin, but not of antivirals (either alone or in combination), azithromycin, and any corticosteroid, was independently associated with lower mortality. Our results support further clinical evaluation of high doses of low molecular weight heparin and tocilizumab as COVID-19 therapeutics.
Identifiants
pubmed: 34697322
doi: 10.1038/s41598-021-00243-4
pii: 10.1038/s41598-021-00243-4
pmc: PMC8545945
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Antibodies, Monoclonal, Humanized
0
Antiviral Agents
0
Azithromycin
83905-01-5
Heparin
9005-49-6
tocilizumab
I031V2H011
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
20964Informations de copyright
© 2021. The Author(s).
Références
J Infect Public Health. 2021 Feb;14(2):263-270
pubmed: 33497876
JAMA. 2020 Oct 6;324(13):1330-1341
pubmed: 32876694
Crit Care. 2020 Nov 23;24(1):653
pubmed: 33225952
JAMA Intern Med. 2021 Jan 1;181(1):12-15
pubmed: 33079980
Eur Respir J. 2020 Jul 30;56(1):
pubmed: 32444413
Lancet. 2020 Sep 12;396(10253):e27-e28
pubmed: 32891216
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440